The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

Recruiting now · Phase 2/Phase 3

Conditions studied: HCC - Hepatocellular Carcinoma

In brief

This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD). The study aims to compare the efficacy differences between sequential therapy and concurrent therapy using bevacizumab and atezolizumab for advanced HCC in MASLD. The research will focus on evaluating objective response rates, progression-free survival, disease control rates, and overall survival, while utilizing biomarker analysis to elucidate treatment mechanisms. Additionally, the study will examine treatment safety, including the incidence and severity of adverse events.

Key facts

Study ID

NCT07285850

Run by

Eastern Hepatobiliary Surgery Hospital

People needed

20

Starts

2025-10-20

Expected to finish

2026-08-30

Last updated by the study team

2025-12-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Excessive alcohol consumption (weekly ethanol intake: males < 210 g, females < 140 g)
• Tumor lesions previously treated with targeted therapy, immunotherapy, TACE, or radiotherapy
• Pregnant or breastfeeding women, or positive pregnancy test at baseline
• Central nervous system metastases diagnosed by CT, MRI, or PET-CT
• Participation in another clinical drug or therapy trial within 4 weeks before first study dose
• Major surgery within 4 weeks prior to first study dose, or incomplete recovery from surgery
• Radiotherapy within 2 weeks before first study dose
• History or presence of primary immunodeficiency or active autoimmune disease
• History of organ transplantation or hematopoietic stem cell transplantation
• Current use of immunosuppressants or corticosteroids (>10 mg/day prednisone or equivalent) within 2 weeks
• Positive for HIV antibody or Treponema pallidum antibody, or active hepatitis B/C infection
• Allergy to recombinant humanized PD-1 monoclonal antibody, VEGF monoclonal antibody, or components
• Symptomatic pleural effusion, pericardial effusion, or ascites requiring clinical intervention
• Severe cardiovascular disease within 12 months (e.g., CAD, CHF ≥ II, arrhythmias, MI)
• Events within 6 months before first dose (e.g., DVT, PE, MI, PCI, ACS, CABG, stroke, TIA, embolism)
• History of GI surgery, obstruction, bleeding, dysfunction, or malabsorption affecting drug absorption
• Severe uncontrolled infection or comorbidity, or moderate/severe renal impairment
• Active pulmonary disease (interstitial pneumonia, COPD, asthma, tuberculosis history)
• Abnormal coagulation (INR > 2.0, PT > 16 s), bleeding tendency, or thrombolytic/anticoagulant therapy (except prophylaxis)
• Significant bleeding within 3 months (e.g., hemoptysis ≥ 2.5 mL, GI bleeding, varices, ulcers, vasculitis)
• Known hereditary/acquired bleeding or thrombotic disorders (e.g., hemophilia, thrombocytopenia)
• History of substance abuse or mental disorders affecting compliance
• Use of warfarin or coumarin derivatives within 14 days before or during treatment
• Other severe acute/chronic conditions increasing risk or confounding results
• Poor compliance or other conditions deemed unsuitable for trial participation

Where it is running

• Eastern Hepatobiliary Surgery Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.